MetaADEDB 2.0 @ LMMD
Antibody test abnormal
(UMLS:C1262046)
UMLS ID:
C1262046
MeSH ID:
N/A
Synonym(s)
1.
Antibody test abnormal
Associated Drug(s)
NameNumber of ReportsReference(s)Data Source
1TriiodothyronineFAERS: 5US FAERS
2ThyroxineFAERS: 4US FAERS
3AtorvastatinFAERS: 3US FAERS
4TacrolimusFAERS: 3US FAERS
5ThyroxineFAERS: 3US FAERS
64-AminopyridineFAERS: 2US FAERS
7CiprofloxacinFAERS: 2US FAERS
8CyclosporineFAERS: 2US FAERS
9Dimethyl FumarateFAERS: 2US FAERS
10IbuprofenFAERS: 2US FAERS
11NicotineFAERS: 2US FAERS
12pomalidomideFAERS: 2US FAERS
134-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamideFAERS: 1US FAERS
14AmiodaroneFAERS: 1US FAERS
15CarbamazepineFAERS: 1US FAERS
16CelecoxibFAERS: 1US FAERS
17CiprofloxacinFAERS: 1US FAERS
18ClindamycinFAERS: 1US FAERS
19CyclophosphamideFAERS: 1US FAERS
20DasatinibFAERS: 1US FAERS
21DeferasiroxFAERS: 1US FAERS
22DiltiazemFAERS: 1US FAERS
23Glatiramer AcetateFAERS: 1US FAERS
24Imatinib MesylateFAERS: 1US FAERS
25IsotretinoinFAERS: 1US FAERS
26LenalidomideFAERS: 1US FAERS
27MinocyclineFAERS: 1US FAERS
28N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideFAERS: 1US FAERS
29PregabalinFAERS: 1US FAERS
30TadalafilFAERS: 1US FAERS
31ledipasvir, sofosbuvir drug combinationFAERS: 1US FAERS
32rofecoxibFAERS: 1US FAERS
33ClomipramineOFFSIDES
34GefitinibOFFSIDES
35MethotrimeprazineOFFSIDES
36NitrazepamOFFSIDES
37NorgestrelOFFSIDES
38TinzaparinCanada Vigilance: 1Canada Vigilance
39Tranexamic AcidOFFSIDES
40UbiquinoneOFFSIDES
41etizolamOFFSIDES
42mizoribineOFFSIDES
43rilmazafoneOFFSIDES
44tulobuterolOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.